Physician profile

Jeffrey Simon Lander

Cardiovascular Disease · Florham Park, NJ

NPI 1356533889

$5,250.98

in general payments reported to CMS, 2019-2025

35 companies · $1,102 in 2025

The $1,102 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,461.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,128.80 2019-2025 Leqvio
Amgen INC. $670.71 2019-2025 Repatha, Repatha
Merck Sharp & Dohme LLC $506.87 2021-2025 Verquvo
Pfizer INC. $387.66 2019-2025
E.R. Squibb & Sons, L.L.C. $305.12 2019-2025 Camzyos, Eliquis
Boston Scientific Corporation $240.31 2019-2025 Watchman Flx, Cds - Mct/Cem Monitoring, Watchman Access System
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $171.10 2023-2025 Lifevest
Janssen Pharmaceuticals, INC $161.84 2019-2022
Philips North America LLC $160.92 2022-2025 (Ck4) Mcot, Extended Holter
Sanofi-Aventis U.S. LLC $155.67 2019-2024
Cvrx, INC. $146.55 2023-2025 Barostim Neo System
Astrazeneca Pharmaceuticals LP $142.12 2019-2024 Farxiga
Amarin Pharma, INC. $128.93 2019-2022
Heartflow, INC. $127.91 2024-2025
Baxter Healthcare $122.22 2023-2025 Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $70.39 2023-2024 Wegovy, Ozempic, Rybelsus
Abbott Laboratories $69.14 2023-2025 Cardiomems, Aveir
Atricure, INC. $67.17 2023
Kiniksa Pharmaceuticals International, Plc $50.61 2024 Arcalyst
Alnylam Pharmaceuticals INC. $48.09 2022-2025 Onpattro
Regeneron Healthcare Solutions, INC. $41.62 2019
Lexicon Pharmaceuticals, INC. $41.46 2023 Inpefa
Bridgebio Pharma, INC. $37.27 2025 Attruby
Boehringer Ingelheim Pharmaceuticals, INC. $31.35 2019-2023 Jardiance
Azurity Pharmaceuticals, INC. $29.40 2023-2024 Edarbi, Edarbi
Kowa Pharmaceuticals America, INC. $29.20 2022
Kestra Medical Technology Services, INC. $27.53 2025 Assure Wcd
Impulse Dynamics (USA) INC. $26.25 2024 Optimizer
Edwards Lifesciences Corporation $22.62 2025 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Bayer Healthcare Pharmaceuticals INC. $21.87 2025
Alexion Pharmaceuticals, INC. $18.21 2025 Strensiq
Altathera Pharmaceuticals LLC $17.81 2021
Scpharmaceuticals INC. $16.76 2023
Kiniksa Pharmaceuticals, LTD. $14.86 2023 Arcalyst
Arbor Pharmaceuticals, INC. $12.64 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeffrey Simon Lander

$5,250.98

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $1,102 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/61967/jeffrey-simon-lander

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.